SOShimpei Otsuka

Shimpei Otsuka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shimpei Otsuka has a total of 118 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Des‐Gamma‐Carboxy Prothrombin Is Associated With Tumor Aggressiveness and Recurrence in Resected Early‐Stage Hepatocellular Carcinoma: A Clinicopathological and Molecular Analysis

    by Katsuhisa Ohgi, Keiichi Ohshima, Michiie Sakamoto, Yae Kanai, Takeshi Nagashima, Ryo Ashida, Shimpei Otsuka, Hideyuki Dei, Satoshi Matsui, Keiichi Hatakeyama, et al.

    Aim: Alpha‐fetoprotein (AFP) and des‐gamma‐carboxy prothrombin (DCP) are widely used tumor markers for hepatocellular carcinoma (HCC); however, their relative prognostic significance in early‐stage disease remains unclear. This study aimed to compare the prognostic impact of AFP and DCP in resected HCC and to explore their underlying molecular characteristics. Methods: We retrospectively analyzed 482 patients who underwent curative resection for HCC. Patients were classified into four groups according to AFP and DCP levels: Negative, AFP‐only, DCP‐only, and Dual‐positive. Recurrence‐free survival (RFS) and prognostic factors were evaluated. In a subset of 204 patients, gene expression profiling was conducted to investigate molecular differences. Results: Among BCLC stage 0/A patients ( n = 406), RFS was stratified according to tumor marker status. The DCP‐only group showed significantly worse RFS than the AFP‐only group (5‐year RFS: 39.5% vs. 52.7%, p = 0.026) and was characterized by larger tumor size (median, 39 vs. 18 mm, p < 0.001) and more frequent portal venous invasion (29% vs. 14%, p = 0.052). Multivariable analysis identified elevated DCP as an independent prognostic factor (hazard ratio 1.48, p = 0.004). In contrast, among stage B/C patients ( n = 76), survival outcomes were uniformly poor and not stratified by tumor marker. Gene expression analysis revealed the upregulation of SFN and downregulation of DCN in DCP‐elevated tumors, suggesting extracellular matrix destabilization that may contribute to tumor aggressiveness. Conclusions: Elevated DCP reflects aggressive tumor biology and identifies patients at high risk of recurrence after resection for BCLC stage 0/A HCC. These findings support the clinical utility of DCP for risk stratification and postoperative surveillance for early‐stage HCC.

  • Impact of CYP2A6 Genotype on Survival Outcomes in Patients With Pancreatic Ductal Adenocarcinoma Receiving Perioperative S-1 Therapy

    by Yuya Miura, Sumiko Ohnami, Keiichi Ohshima, Takeshi Nagashima, Yukiyasu Okamura, Keiichi Hatakeyama, Kenichi Urakami, Yasuto Akiyama, Ryo Ashida, Katsuhisa Ohgi, et al.

    Objective: To evaluate the impact of CYP2A6 genetic polymorphisms on survival outcomes in patients with pancreatic ductal adenocarcinoma (PDAC) receiving perioperative S-1 therapy. Background: S-1, an oral fluoropyrimidine containing tegafur, is widely used for perioperative treatment of PDAC in Japan. Tegafur requires metabolic activation to 5-fluorouracil, primarily by CYP2A6 . Given the high prevalence of reduced-function CYP2A6 variants in East Asian populations, their clinical significance in PDAC remains unclear. Methods: This retrospective study included 145 patients with PDAC who underwent curative resection and received adjuvant S-1, including 78 patients who had received S-1–containing neoadjuvant therapy. Germline CYP2A6 variants were identified using whole-exome sequencing of peripheral blood samples. Decreased-function alleles (*4, *7, *9) and the rare nonsense allele *48 were evaluated. Patients were classified into poor, intermediate, and normal metabolizer groups. Survival outcomes were analyzed using Kaplan-Meier and Cox regression analyses. Results: Decreased-function CYP2A6 genotypes were identified in 82 patients (56.6%), including 6 poor metabolizers (4.1%). These patients had a higher frequency of lymph node metastasis than those with normal genotypes (78.0% vs. 52.4%, P =0.001). Recurrence-free survival (RFS) was significantly shorter (median, 19.2 vs. 32.3 mo; P =0.040), whereas overall survival (OS) was shorter but not statistically significant (47.9 vs. 62.2 mo; P =0.104). In multivariable analysis, CYP2A6 poor metabolizer status was independently associated with OS (HR, 3.17; 95% CI, 1.06–9.46; P =0.039). Among the 78 patients who received S-1–containing neoadjuvant therapy, both OS and RFS were significantly worse in those with decreased-function genotypes. Conclusions: Decreased CYP2A6 functional genotypes were associated with poorer oncological outcomes in patients with PDAC receiving perioperative S-1 therapy, suggesting that the CYP2A6 genotype may serve as a biomarker for optimizing treatment strategies.

  • Open Access

    Impact of Recanalization on Liver Hypertrophy after Portal Vein Embolization and the Role of Re‐Embolization

    by Masao Uemura, Shimpei Otsuka, Ryo Ashida, Katsuhisa Ohgi, Mihoko Yamada, Rui Sato, Takeshi Aramaki, Akifumi Notsu, Katsuhiko Uesaka, Teiichi Sugiura

    Background: Portal vein recanalization following portal vein embolization (PVE) can impair future liver remnant (FLR) growth; however, the clinical significance of recanalization and the utility of re‐embolization remain unclear. This study aimed to assess the incidence of recanalization after PVE, its impact on liver regeneration, and the efficacy of re‐embolization. Methods: We retrospectively analyzed 249 consecutive patients who underwent hepatectomy following right PVE between 2010 and 2022. Recanalization was classified as major (section or segment) or minor (less than one segment). In this study, FLR was defined as the left hemiliver for standardization across different surgical procedures. Liver hypertrophy was assessed using the degree of hypertrophy (DH) and the kinetic growth rate (KGR). Re‐embolization was performed in selected patients with insufficient FLR growth due to recanalization. Results: Recanalization occurred in 89 patients (36%), including 55 minor and 34 major recanalizations. DH and KGR differed significantly among the three groups. Subsequent post hoc analysis revealed that major recanalization had significantly lower DH ( p = 0.002) and KGR ( p = 0.003) than non‐recanalization. Seven patients underwent re‐embolization, which significantly improved the FLR ratio (34.2% to 39.8%, p = 0.003) without complications. Conclusions: Major recanalization after PVE was significantly associated with impaired liver regeneration. Re‐embolization is a potentially effective strategy for managing insufficient FLR growth due to recanalization, particularly in cases of major recanalization.


  • Open Access

    Management Strategies for Disappearing Colorectal Liver Metastases After Systemic Chemotherapy: Long‐Term Outcomes and Preoperative Prediction of ‘True Complete Response’

    by Taihei Soma, Ryo Ashida, Takeshi Kawakami, Katsuhisa Ohgi, Mihoko Yamada, Shimpei Otsuka, Yoshiyasu Kato, Kentaro Yamazaki, Katsuhiko Uesaka, Teiichi Sugiura

    Background: Determining whether to resect disappearing liver metastases (DLMs) after chemotherapy for colorectal liver metastases (CRLMs) remains challenging. Methods: Patients who underwent hepatectomy after systemic chemotherapy for initially unresectable CRLMs were reviewed. True complete response (CR) was defined as either resected DLMs with pathological CR or unresected DLMs without local recurrence. Long‐term outcomes were compared between patients with and without resection of all DLMs. Results: Among 58 patients, 26 (44.8%) had DLMs, totaling 106 lesions. True CR was achieved in 70.8% of DLM lesions. Long‐term outcomes did not differ between patients with and without resection of all DLMs (median recurrence‐free survival, 11.1 vs. 7.6 months, p = 0.594; median surgical failure‐free survival, 11.1 vs. 17.2 months, p = 0.758; median overall survival, 43.6 vs. 53.6 months, p = 0.819). DLM lesions with true CR had smaller initial diameters than those without true CR (5 vs. 9 mm, p = 0.013). Conclusion: Regardless of whether all DLMs were resected, patients had acceptable long‐term outcomes. DLM lesions with a larger initial diameter before chemotherapy may warrant proactive intraoperative exploration for residual disease using contrast‐enhanced ultrasonography.


  • Open Access

    Reappraising the prognostic role of liver resection as part of extended cholecystectomy for T2 gallbladder cancer

    by Hirotoshi Noda, Yoshiyasu Kato, Ryo Ashida, Katsuhisa Ohgi, Shimpei Otsuka, Hideyuki Dei, Katsuhiko Uesaka, Teiichi Sugiura

  • Open Access

    Proposal of Early Drain Exchange After Pancreatoduodenectomy From the View of Reducing Postoperative Pancreatic Fistula

    by Taihei Soma, Mihoko Yamada, Ryo Ashida, Katsuhisa Ohgi, Shimpei Otsuka, Yoshiyasu Kato, Teiichi Sugiura, Katsuhiko Uesaka

    Background: To mitigate the progression of postoperative pancreatic fistula (POPF) after pancreatoduodenectomy (PD), appropriate drain management is required, and exchanging drainage tubes is commonly performed. However, the optimal timing of the first drain exchange has not yet been determined. Methods: Among 481 patients who underwent PD between 2019 and 2023, 173 (36.0%) whose drain fluid amylase activity on postoperative day (POD) 3 was ≥ 375 U/L and who underwent drain exchange were classified into 2 groups according to the timing of the first drain exchange: the early group (POD 5 or earlier, n = 74) and the standard group (POD 6 or later, n = 99). The incidence of POPF, duration of drain placement, and length of postoperative hospital stay were compared. Results: Of the overall 481 patients, grade B POPF occurred in 117 (24.3%) patients, with no grade C POPF. Among the 173 patients analyzed, the early group had a lower proportion of grade B POPF (47.3% vs. 73.7%, p < 0.001), shorter drain placement (21 days vs. 27 days, p = 0.001), and shorter hospital stay (23 days vs. 33 days, p = 0.003) than the standard group. A multivariate analysis revealed that performing the first drain exchange on POD 6 or later was a risk factor for grade B POPF. Conclusion: Performing the first drain exchange early after PD was associated with a reduced incidence of POPF, shorter drain duration, and shorter hospital stay. This approach may improve the drainage efficiency.

  • Open Access

    Prognostic impact and predictive model for early non-curative recurrence after liver resection for hepatocellular carcinoma: a retrospective cohort study

    by Jun Shibamoto, Michihisa Moriguchi, Akifumi Notsu, Keita Mori, Ryo Ashida, Katsuhisa Ohgi, Shimpei Otsuka, Yoshiyasu Kato, Hideyuki Dei, Katsuhiko Uesaka, et al.

    Background: The prognostic impact of early non-curative recurrence after liver resection for hepatocellular carcinoma (HCC) and its predictive factors remain unknown. We aimed to identify independent predictive factors for early non-curative recurrence, develop a predictive model, and evaluate its clinical utility. Materials and Methods: We retrospectively analyzed 624 patients who underwent curative HCC resection between 2002 and 2020. Patients were randomly assigned to training ( n = 416) and validation ( n = 208) sets. Early recurrence was defined as recurrence within 2 years after surgery. Non-curative recurrence was defined as recurrence corresponding to the intermediate or advanced stage of the Barcelona Clinic Liver Cancer staging system based on tumor factors. A nomogram was constructed based on independent predictive factors identified via multivariate analysis. Model performance was assessed by the area under the receiver operating characteristic curve (AUC), calibration plots, and decision curve analysis. Results: Early non-curative recurrence was an independent prognostic factor for overall survival (OS) after surgery and OS after recurrence (hazard ratio = 5.387 and 2.806, P P P <0.001). Five factors were independently associated with early non-curative recurrence: alpha-fetoprotein, tumor size, number of tumors, portal invasion, and serosal invasion. The predictive model demonstrated high calibration performance in the training (AUC = 0.825) and validation (AUC = 0.792) sets. Decision curve analysis confirmed the clinical utility of the predictive model. Conclusion: We developed and validated a novel predictive model for early non-curative recurrence, which is significantly associated with poor prognosis after curative liver resection for HCC. Its application may enhance individualized postoperative surveillance and treatment strategies, potentially improving long-term outcomes.


  • Open Access

    Tumor Mutational Burden as a Prognostic Biomarker for Relapse-Free Survival in Hepatocellular Carcinoma: Insights from Long-Term Follow-Up

    by Yuya Miura, Yukiyasu Okamura, Keiichi Ohshima, Takeshi Nagashima, Teiichi Sugiura, Ryo Ashida, Katsuhisa Ohgi, Yoshiyasu Kato, Shimpei Otsuka, Hideyuki Dei, et al.

    Background. Hepatocellular carcinoma (HCC) has a high recurrence rate even after curative resection. Although the tumor mutational burden (TMB) has emerged as a potential biomarker for survival outcomes in HCC, its clinical significance remains unclear. Methods. A retrospective analysis of 204 patients who underwent an initial liver resection was performed. Patients were classified into TMB-high (≥4.8 mutations/Mb) or TMB-low groups based on whole-exome sequencing. We assessed relapse-free survival (RFS), overall survival (OS), and performed subgroup analyses focusing on patients without recurrence within the first two postoperative years. Gene expression profiling and mutational signature analyses were also conducted. Results. Patients with TMB-high tumors showed significantly shorter RFS compared to the TMB-low group (median 24.2 vs. 37.1 months; p=0.008), whereas OS was not significantly different. Multivariate analysis identified TMB-high status as an independent prognostic factor for RFS (HR, 1.72; p=0.011). In the subgroup without early recurrence, TMB-high status was the only independent factor associated with late recurrence (HR, 2.45; p=0.005). TMB-high tumors correlated with advanced liver fibrosis and specific somatic mutations (CTNNB1, TTN, MUC16). Additionally, mutational signatures associated with chronic inflammation and alcohol consumption were enriched in the TMB-high group. Conclusions. High TMB is associated with shorter relapse-free survival in HCC, particularly among patients with long-term follow-up, indicating an increased risk for multicentric recurrence. TMB may serve as a valuable prognostic biomarker for recurrence risk stratification. The associations between TMB, liver fibrosis, and inflammation suggest potential therapeutic strategies targeting the hepatic microenvironment to reduce recurrence risk in patients undergoing liver resection for HCC.


  • Prognostic significance of the cachexia index for patients with perihilar cholangiocarcinoma

    by Katsuya Sakashita, Shimpei Otsuka, Ryo Ashida, Katsuhisa Ohgi, Yoshiyasu Kato, Hideyuki Dei, Akifumi Notsu, Katsuhiko Uesaka, Teiichi Sugiura


  • Open Access

    Comparable impact of lymph node metastases in T2 gallbladder cancer on postoperative prognosis irrespective of the extent of the metastases: A retrospective analysis

    by Yoji Kishi, Teiichi Sugiura, Takashi Mizuno, Hiromichi Ito, Yu Takahashi, Takehiro Noji, Yuta Abe, Shimpei Otsuka, Shoji Kawakatsu, Asayo Kato, et al.

    Background: Lymph node metastases beyond the hepatoduodenal ligament are sometimes encountered in locally limited T2 gallbladder cancer (GBCA). However, the incidence and impact on prognosis remain unclear.Methods: This was a retrospective multi‐institutional study of patients who underwent surgical resection for GBCA from 2002 to 2022. The eighth edition of the Union for International Cancer Control staging was used for tumor‐node‐metastasis categorization. The lymph node location was classified as follows: (A) along the hepatoduodenal ligament and common hepatic artery; (B) posterior side of the pancreatic head; and (C) others. Metastasis to regions A, B, and C nodes was denoted as Na, Nb, and Nc, respectively.Results: Data for 379 patients (pT1, 29; pT2, 162: pT3, 141; and pT4, 47) were evaluated; none with pT1 GBCA had node metastasis. For N1/2 GBCA, the proportion of patients with N2 disease increased with increasing T grade (p = .001), while the proportions of patients with Na, Nb, and Nc disease were comparable between pT2 (61%, 26%, and 13%), pT3 (63%, 26%, and 12%), and pT4 (50%, 38%, and 12%) disease (p = .681), respectively. Overall survival for pT2N1/2 disease (5 years, 43.8%) was comparable to that for pT3/4N0 disease (5 years, 37.2%; p = .192). Among patients with node‐positive pT2 disease, overall survival was comparable for Na, Nb, and Nc disease, with 5‐year survivals of 46%, 43%, and 31%, respectively (p = .346).Conclusion: Region B or C node metastasis was not rare even in pT2 GBCA. Regarding survival outcomes, pT2 node‐positive GBCA should be considered advanced disease irrespective of the extent of node metastasis.